McKesson (FRA:MCK) EBITDA Margin %: 2.47% (As of Mar. 2026) — 93% Above Median


FRA:MCK McKesson Corp FRA:MCK
86 GF Score
Price €667.60
GF Value €688.81
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is McKesson EBITDA Margin %?

McKesson FRA:MCK +3.41% 86 EBITDA Margin % is 2.47% as of Mar. 2026, which is 93% above its 10-year median of 1.28. GuruFocus rates FRA:MCK with a GF Score™ of 86/100 and a GF Value™ of €688.81 (Fairly Valued). The stock has 2 warning signs investors should review. Among 119 Medical Distribution companies, McKesson ranks worse than 77.31% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. McKesson's EBITDA for the three months ended in Mar. 2026 was €2,060 Mil. McKesson's Revenue for the three months ended in Mar. 2026 was €83,295 Mil. Therefore, McKesson's EBITDA margin for the quarter that ended in Mar. 2026 was 2.47%.


McKesson  (FRA:MCK) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


McKesson EBITDA Margin % Related Terms


McKesson EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for McKesson's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

McKesson EBITDA Margin % Chart

McKesson Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.09 1.98 1.51 1.46 1.78

McKesson Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.88 1.28 1.61 1.77 2.47

FRA:MCK vs COR, CAH, HSIC: EBITDA Margin % Comparison

For the Medical Distribution subindustry, McKesson's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


McKesson EBITDA Margin % vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, McKesson's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where McKesson's EBITDA Margin % falls into.


FRA:MCK
86GF Score
McKesson Corp FRA:MCK
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

McKesson EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

McKesson's EBITDA Margin % for the fiscal year that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2026 )/Revenue (A: Mar. 2026 )
=6208.105/348966.95
=1.78 %

McKesson's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=2060.43/83295.175
=2.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 2.47% mean?
McKesson (FRA:MCK) has a EBITDA Margin % of 2.47% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on McKesson and its competitors. This is 93% above median its historical median of 1.28. According to the industry distribution chart, McKesson ranks #92 out of 119 companies in the Medical Distribution industry, placing it in the top 77.3%.
Is McKesson's EBITDA Margin % too high?
McKesson's current EBITDA Margin % of 2.47% is 93% above median its 10-year median of 1.28. The Medical Distribution industry median EBITDA Margin % is 4.31. McKesson's value of 2.47% is 42.7% below this industry median. Based on the distribution chart, McKesson ranks #92 out of 119 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, McKesson has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does McKesson's EBITDA Margin % compare to COR and CAH?
According to the Medical Distribution industry distribution chart, McKesson ranks #92 out of 119 companies for EBITDA Margin %. This places McKesson in the lower half of its industry. The industry median EBITDA Margin % is 4.31. McKesson's value of 2.47% is 42.7% below this benchmark. While the company's 10-year median is 1.28 vs. the industry median of 4.31, McKesson has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. McKesson's current EBITDA Margin % of 2.47% is 42.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on McKesson and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. McKesson's current EBITDA Margin % is 2.47%, which is 93% above median its own 10-year median of 1.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is McKesson stock overvalued right now?
Based on GuruFocus' analysis, McKesson (FRA:MCK) is currently considered Fairly Valued. The stock's GF Value™ is €688.81, compared to a current price of €667.60 — trading 3.1% below its estimated fair value. The current EBITDA Margin % is 2.47%, which is 93% above median its 10-year median of 1.28 and 42.7% below the Medical Distribution industry median of 4.31. McKesson's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For McKesson (FRA:MCK), the current EBITDA Margin % is 2.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is McKesson (FRA:MCK) Overvalued in 2026?

Based on GuruFocus' analysis, McKesson stock appears to be undervalued. The current stock price of €667.60 is trading 3.1% below its estimated GF Value™ of €688.81. GuruFocus considers McKesson to be Fairly Valued.

Key valuation signals for FRA:MCK:

  • EBITDA Margin %: 2.47% (93% above median its 10-year median of 1.28)
  • GF Value™: €688.81 vs. price of €667.60 (3.1% below fair value)
  • GF Score™: 86/100 with 2 warning signs
  • Industry Position: 42.7% below the Medical Distribution median (#92 of 119)

No single metric tells the full story. See the FRA:MCK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


McKesson Business Description

Address 6555 State Highway 161, Irving, TX, USA, 75039
McKesson is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
86GF Score

Get the complete analysis for FRA:MCK

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€667.60
Price
€688.81
GF Value